ONTOLOGY REPORT - ANNOTATIONS
| Term: | staurosporine |
|
| Accession: | CHEBI:15738
|
browse the term
|
| Definition: | An indolocarbazole alkaloid that has formula C28H26N4O3. |
| Synonyms: | exact_synonym: | (5S,6R,7R,9R)-6-methoxy-5-methyl-7-methylamino-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one |
| | related_synonym: | C28H26N4O3; CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13; InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1; InChIKey=HKSZLNNOFSGOKW-FYTWVXJKSA-N; Staurosporin |
| | alt_id: | CHEBI:15106; CHEBI:45788; CHEBI:9252 |
| | xref_casrn: | 62996-74-1 |
| | xref: | ChEMBL:473381 "ChEMBL COMPOUND"; ChemIDplus:62996-74-1 "CAS Registry Number"; DrugBank:DB02010 "DrugBank"; KEGG COMPOUND:62996-74-1 "CAS Registry Number"; KEGG COMPOUND:C02079 "KEGG COMPOUND" |
| | xref_mesh: | MESH:D019311 |
| | cyclic_relationship: | is_conjugate_base_of CHEBI:57491 |
|
|
staurosporine
|
| G |
Abcb11 |
ATP-binding cassette, subfamily B (MDR/TAP), member 11 |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
increases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
EXP |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
increases phosphorylation |
EXP |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
multiple interactions |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
multiple interactions |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
Atg12 |
autophagy related 12 |
|
affects response to substance |
ISO |
18 |
40,933,793 |
40,943,970 |
RGD:6480464 |
CTD |
| G |
Atg7 |
autophagy related 7 |
|
affects response to substance |
ISO |
4 |
150,814,706 |
150,992,704 |
RGD:6480464 |
CTD |
| G |
Atp2a2 |
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 |
|
decreases expression |
EXP |
12 |
35,266,600 |
35,316,237 |
RGD:6480464 |
CTD |
| G |
Bag3 |
Bcl2-associated athanogene 3 |
|
decreases response to substance |
ISO |
1 |
187,781,147 |
187,804,835 |
RGD:6480464 |
CTD |
| G |
Bag3 |
Bcl2-associated athanogene 3 |
|
multiple interactions |
ISO |
1 |
187,781,147 |
187,804,835 |
RGD:6480464 |
CTD |
| G |
Bag3 |
Bcl2-associated athanogene 3 |
|
decreases expression |
ISO |
1 |
187,781,147 |
187,804,835 |
RGD:6480464 |
CTD |
| G |
Bag4 |
BCL2-associated athanogene 4 |
|
decreases expression |
ISO |
16 |
70,663,821 |
70,680,671 |
RGD:6480464 |
CTD |
| G |
Bag6 |
BCL2-associated athanogene 6 |
|
decreases expression |
ISO |
20 |
3,739,593 |
3,752,311 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
affects expression |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
affects localization |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
affects expression |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
decreases response to substance |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
decreases response to substance |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
decreases response to substance |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
increases expression |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Becn1 |
beclin 1, autophagy related |
|
multiple interactions |
ISO |
10 |
90,317,957 |
90,333,329 |
RGD:6480464 |
CTD |
| G |
Becn1 |
beclin 1, autophagy related |
|
decreases response to substance |
ISO |
10 |
90,317,957 |
90,333,329 |
RGD:6480464 |
CTD |
| G |
Bid |
BH3 interacting domain death agonist |
|
increases expression |
ISO |
4 |
157,296,383 |
157,318,481 |
RGD:6480464 |
CTD |
| G |
Bid |
BH3 interacting domain death agonist |
|
multiple interactions |
ISO |
4 |
157,296,383 |
157,318,481 |
RGD:6480464 |
CTD |
| G |
Birc3 |
baculoviral IAP repeat-containing 3 |
|
decreases response to substance |
ISO |
8 |
4,682,202 |
4,696,856 |
RGD:6480464 |
CTD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
|
affects expression |
ISO |
3 |
105,063,018 |
105,116,145 |
RGD:6480464 |
CTD |
| G |
Casp1 |
caspase 1 |
|
multiple interactions |
ISO |
8 |
2,027,976 |
2,036,872 |
RGD:6480464 |
CTD |
| G |
Casp1 |
caspase 1 |
|
affects localization |
ISO |
8 |
2,027,976 |
2,036,872 |
RGD:6480464 |
CTD |
| G |
Casp1 |
caspase 1 |
|
increases activity |
ISO |
8 |
2,027,976 |
2,036,872 |
RGD:6480464 |
CTD |
| G |
Casp2 |
caspase 2 |
|
increases cleavage |
ISO |
4 |
70,029,728 |
70,047,164 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases cleavage |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases cleavage |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp7 |
caspase 7 |
|
increases activity |
ISO |
1 |
262,689,300 |
262,721,591 |
RGD:6480464 |
CTD |
| G |
Casp7 |
caspase 7 |
|
multiple interactions |
EXP |
1 |
262,689,300 |
262,721,591 |
RGD:6480464 |
CTD |
| G |
Casp7 |
caspase 7 |
|
increases activity |
EXP |
1 |
262,689,300 |
262,721,591 |
RGD:6480464 |
CTD |
| G |
Casp7 |
caspase 7 |
|
increases activity |
ISO |
1 |
262,689,300 |
262,721,591 |
RGD:6480464 |
CTD |
| G |
Casp7 |
caspase 7 |
|
increases activity |
ISO |
1 |
262,689,300 |
262,721,591 |
RGD:6480464 |
CTD |
| G |
Casp7 |
caspase 7 |
|
increases activity |
ISO |
1 |
262,689,300 |
262,721,591 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
multiple interactions |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
increases activity |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Ccr5 |
chemokine (C-C motif) receptor 5 |
|
multiple interactions |
EXP |
8 |
128,907,157 |
128,912,272 |
RGD:6480464 |
CTD |
| G |
Cd28 |
Cd28 molecule |
|
multiple interactions |
ISO |
9 |
59,342,273 |
59,367,743 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
multiple interactions |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
multiple interactions |
ISO |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
|
multiple interactions |
ISO |
1 |
211,351,738 |
211,353,120 |
RGD:6480464 |
CTD |
| G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
|
multiple interactions |
ISO |
1 |
211,351,738 |
211,353,120 |
RGD:6480464 |
CTD |
| G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
|
affects binding |
ISO |
1 |
211,351,738 |
211,353,120 |
RGD:6480464 |
CTD |
| G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
|
multiple interactions |
ISO |
4 |
63,911,292 |
63,913,354 |
RGD:6480464 |
CTD |
| G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
|
affects binding |
EXP |
17 |
71,214,906 |
71,218,463 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
multiple interactions |
ISO |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Csnk2a2 |
casein kinase 2, alpha prime polypeptide |
|
affects expression |
ISO |
19 |
10,015,369 |
10,054,662 |
RGD:6480464 |
CTD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
increases phosphorylation |
EXP |
8 |
125,978,161 |
125,987,670 |
RGD:6480464 |
CTD |
| G |
Cxcr1 |
chemokine (C-X-C motif) receptor 1 |
|
multiple interactions |
EXP |
9 |
73,510,488 |
73,511,537 |
RGD:6480464 |
CTD |
| G |
Cxcr4 |
chemokine (C-X-C motif) receptor 4 |
|
multiple interactions |
EXP |
13 |
41,308,286 |
41,312,190 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
EXP |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
EXP |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
multiple interactions |
EXP |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
increases expression |
EXP |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Dedd |
death effector domain-containing |
|
affects expression |
ISO |
13 |
87,238,315 |
87,241,703 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
decreases activity |
EXP |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Ednrb |
endothelin receptor type B |
|
multiple interactions |
EXP |
15 |
87,893,141 |
87,898,700 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
EXP |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Epo |
erythropoietin |
|
decreases response to substance |
EXP |
12 |
19,551,768 |
19,555,208 |
RGD:6480464 |
CTD |
| G |
Epo |
erythropoietin |
|
multiple interactions |
EXP |
12 |
19,551,768 |
19,555,208 |
RGD:6480464 |
CTD |
| G |
Ercc5 |
excision repair cross-complementing rodent repair deficiency, complementation group 5 |
|
affects expression |
ISO |
9 |
43,248,023 |
43,293,196 |
RGD:6480464 |
CTD |
| G |
F3 |
coagulation factor III (thromboplastin, tissue factor) |
|
multiple interactions |
ISO |
2 |
218,371,050 |
218,382,645 |
RGD:6480464 |
CTD |
| G |
Fn1 |
fibronectin 1 |
|
multiple interactions |
EXP |
9 |
70,702,181 |
70,771,155 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
|
multiple interactions |
ISO |
8 |
82,724,429 |
82,762,848 |
RGD:6480464 |
CTD |
| G |
Gclm |
glutamate cysteine ligase, modifier subunit |
|
multiple interactions |
ISO |
2 |
218,895,434 |
218,915,491 |
RGD:6480464 |
CTD |
| G |
Gfap |
glial fibrillary acidic protein |
|
multiple interactions |
EXP |
10 |
92,059,881 |
92,068,555 |
RGD:6480464 |
CTD |
| G |
Gsta2 |
glutathione S-transferase alpha 2 |
|
multiple interactions |
EXP |
8 |
83,299,249 |
83,312,958 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hr |
hair growth associated |
|
multiple interactions |
ISO |
15 |
50,957,053 |
50,972,842 |
RGD:6480464 |
CTD |
| G |
Hr |
hair growth associated |
|
affects response to substance |
ISO |
15 |
50,957,053 |
50,972,842 |
RGD:6480464 |
CTD |
| G |
Hr |
hair growth associated |
|
multiple interactions |
EXP |
15 |
50,957,053 |
50,972,842 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
multiple interactions |
EXP |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
affects activity |
EXP |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Il5 |
interleukin 5 |
|
decreases activity |
ISO |
10 |
39,177,786 |
39,180,657 |
RGD:6480464 |
CTD |
| G |
Ins1 |
insulin 1 |
|
multiple interactions |
EXP |
1 |
258,001,134 |
258,001,688 |
RGD:6480464 |
CTD |
| G |
Ins2 |
insulin 2 |
|
multiple interactions |
EXP |
1 |
202,935,548 |
202,936,379 |
RGD:6480464 |
CTD |
| G |
Itgal |
integrin, alpha L |
|
multiple interactions |
ISO |
1 |
186,561,795 |
186,598,908 |
RGD:6480464 |
CTD |
| G |
Itgb2 |
integrin, beta 2 |
|
multiple interactions |
ISO |
20 |
11,446,521 |
11,485,009 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
EXP |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Kng1 |
kininogen 1 |
|
decreases activity |
EXP |
11 |
80,109,499 |
80,131,887 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapt |
microtubule-associated protein tau |
|
multiple interactions |
ISO |
10 |
93,411,098 |
93,508,762 |
RGD:6480464 |
CTD |
| G |
Mapt |
microtubule-associated protein tau |
|
multiple interactions |
EXP |
10 |
93,411,098 |
93,508,762 |
RGD:6480464 |
CTD |
| G |
Mark1 |
MAP/microtubule affinity-regulating kinase 1 |
|
multiple interactions |
ISO |
13 |
100,905,369 |
101,009,161 |
RGD:6480464 |
CTD |
| G |
Mcl1 |
myeloid cell leukemia sequence 1 |
|
increases cleavage |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Mcl1 |
myeloid cell leukemia sequence 1 |
|
decreases response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Mdm2 |
p53 E3 ubiquitin protein ligase |
|
multiple interactions |
ISO |
7 |
56,996,694 |
57,020,926 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mt1a |
metallothionein 1a |
|
multiple interactions |
ISO |
19 |
11,261,631 |
11,262,647 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
multiple interactions |
ISO |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
decreases response to substance |
ISO |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Nefl |
neurofilament, light polypeptide |
|
multiple interactions |
EXP |
15 |
47,636,303 |
47,640,176 |
RGD:6480464 |
CTD |
| G |
Nefm |
neurofilament, medium polypeptide |
|
multiple interactions |
EXP |
15 |
47,698,371 |
47,703,350 |
RGD:6480464 |
CTD |
| G |
Ngf |
nerve growth factor (beta polypeptide) |
|
multiple interactions |
ISO |
2 |
197,621,726 |
197,632,960 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nppa |
natriuretic peptide A |
|
multiple interactions |
EXP |
5 |
165,074,518 |
165,075,827 |
RGD:6480464 |
CTD |
| G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
|
multiple interactions |
EXP |
19 |
37,251,147 |
37,266,040 |
RGD:6480464 |
CTD |
| G |
Ntf3 |
neurotrophin 3 |
|
multiple interactions |
EXP |
4 |
162,435,781 |
162,506,961 |
RGD:6480464 |
CTD |
| G |
Ntf3 |
neurotrophin 3 |
|
multiple interactions |
EXP |
4 |
162,435,781 |
162,506,961 |
RGD:6480464 |
CTD |
| G |
Nts |
neurotensin |
|
multiple interactions |
ISO |
7 |
40,474,654 |
40,484,058 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
increases cleavage |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
increases cleavage |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
increases cleavage |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Ppp2r2b |
protein phosphatase 2, regulatory subunit B, beta |
|
affects localization |
EXP |
18 |
35,865,837 |
36,318,308 |
RGD:6480464 |
CTD |
| G |
Ppp3ca |
protein phosphatase 3, catalytic subunit, alpha isozyme |
|
decreases response to substance |
ISO |
2 |
234,130,176 |
234,409,232 |
RGD:6480464 |
CTD |
| G |
Ppp3ca |
protein phosphatase 3, catalytic subunit, alpha isozyme |
|
increases cleavage |
ISO |
2 |
234,130,176 |
234,409,232 |
RGD:6480464 |
CTD |
| G |
Prdx1 |
peroxiredoxin 1 |
|
multiple interactions |
ISO |
5 |
136,975,780 |
136,991,630 |
RGD:6480464 |
CTD |
| G |
Prkca |
protein kinase C, alpha |
|
multiple interactions |
ISO |
10 |
97,367,196 |
97,638,910 |
RGD:6480464 |
CTD |
| G |
Prkca |
protein kinase C, alpha |
|
multiple interactions |
EXP |
10 |
97,367,196 |
97,638,910 |
RGD:6480464 |
CTD |
| G |
Prkca |
protein kinase C, alpha |
|
multiple interactions |
EXP |
10 |
97,367,196 |
97,638,910 |
RGD:6480464 |
CTD |
| G |
Prkcd |
protein kinase C, delta |
|
multiple interactions |
ISO |
16 |
5,954,218 |
5,975,743 |
RGD:6480464 |
CTD |
| G |
Prkcd |
protein kinase C, delta |
|
multiple interactions |
EXP |
16 |
5,954,218 |
5,975,743 |
RGD:6480464 |
CTD |
| G |
Psen2 |
presenilin 2 |
|
multiple interactions |
ISO |
13 |
95,934,674 |
95,951,836 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ret |
ret proto-oncogene |
|
decreases expression |
EXP |
4 |
154,448,179 |
154,491,103 |
RGD:6480464 |
CTD |
| G |
Slc1a1 |
solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1 |
|
decreases activity |
EXP |
1 |
232,469,746 |
232,549,584 |
RGD:6480464 |
CTD |
| G |
Slc30a1 |
solute carrier family 30 (zinc transporter), member 1 |
|
multiple interactions |
ISO |
13 |
107,980,864 |
107,986,519 |
RGD:6480464 |
CTD |
| G |
Slc5a6 |
solute carrier family 5 (sodium-dependent vitamin transporter), member 6 |
|
multiple interactions |
ISO |
6 |
25,301,630 |
25,312,901 |
RGD:6480464 |
CTD |
| G |
Snca |
synuclein, alpha (non A4 component of amyloid precursor) |
|
multiple interactions |
ISO |
4 |
89,613,731 |
89,722,807 |
RGD:6480464 |
CTD |
| G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
|
multiple interactions |
ISO |
3 |
8,956,380 |
9,021,831 |
RGD:6480464 |
CTD |
| G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
|
increases cleavage |
ISO |
3 |
8,956,380 |
9,021,831 |
RGD:6480464 |
CTD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
multiple interactions |
ISO |
10 |
89,821,078 |
89,872,970 |
RGD:6480464 |
CTD |
| G |
Syncrip |
synaptotagmin binding, cytoplasmic RNA interacting protein |
|
multiple interactions |
ISO |
8 |
93,730,131 |
93,820,288 |
RGD:6480464 |
CTD |
| G |
Tjp1 |
tight junction protein 1 |
|
multiple interactions |
EXP |
1 |
119,684,774 |
119,750,532 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
EXP |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
UST4r |
integral membrane transport protein UST4r |
|
multiple interactions |
ISO |
1 |
210,618,706 |
210,688,125 |
RGD:6480464 |
CTD |
| G |
Vasp |
vasodilator-stimulated phosphoprotein |
|
multiple interactions |
ISO |
1 |
78,621,494 |
78,636,762 |
RGD:6480464 |
CTD |
| G |
Vdac1 |
voltage-dependent anion channel 1 |
|
multiple interactions |
EXP |
10 |
37,795,721 |
37,823,253 |
RGD:6480464 |
CTD |
| G |
Vdr |
vitamin D (1,25- dihydroxyvitamin D3) receptor |
|
increases cleavage |
ISO |
7 |
136,567,614 |
136,617,280 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
multiple interactions |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
multiple interactions |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vim |
vimentin |
|
multiple interactions |
EXP |
17 |
87,847,280 |
87,855,763 |
RGD:6480464 |
CTD |
| G |
Wt1 |
Wilms tumor 1 |
|
increases expression |
ISO |
3 |
90,529,704 |
90,577,280 |
RGD:6480464 |
CTD |
midostaurin
|
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
EXP |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Flt3 |
fms-related tyrosine kinase 3 |
|
decreases response to substance |
ISO |
12 |
8,193,629 |
8,268,682 |
RGD:6480464 |
CTD |
| G |
Flt3 |
fms-related tyrosine kinase 3 |
|
decreases activity |
ISO |
12 |
8,193,629 |
8,268,682 |
RGD:6480464 |
CTD |
| G |
Jak2 |
Janus kinase 2 |
|
increases phosphorylation |
ISO |
1 |
232,915,995 |
232,974,763 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mpl |
myeloproliferative leukemia virus oncogene |
|
increases expression |
ISO |
5 |
138,921,281 |
138,931,990 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
Term paths to the root
|